Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT03787056 Recruiting - Breast Cancer Clinical Trials

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

ONCOPRO
Start date: December 4, 2018
Phase: N/A
Study type: Interventional

Progastrin is a pro-hormone that, in physiological conditions, is maturated in gastrin in G cells of the stomach. The role of the gastrin is to stimulate the secretion of gastric acids during digestion. It is also important for the regulation of cell growth of the gastric mucosal. In a healthy person, progastrin is not detectable in the peripheral blood. However, progastrin is abnormally released in the blood of patients with different cancers (colorectal, gastric, ovarian, breast, cervix uterus, melanoma…) The gene GAST coding for progastrin is a direct target gene of the WNT/ß-catenin oncogenic pathway. The activation of this oncogenic pathway is an early event in cancer development. Chronic activation of the WNT/ß-catenin oncogenic pathway occurs in almost all human solid tumors and is a central mechanism in cancer biology that induces cellular proliferation, blocking of differentiation leading to primary tumor growth and metastasis formation. Progastrin measured in the peripheral blood of patients on treatments, could be a new powerful marker for diagnosis and prognosis at different stages.

NCT ID: NCT03786848 Not yet recruiting - Prostate Cancer Clinical Trials

Personalized Mini-PDX for Metastatic CRPC

Start date: December 26, 2018
Phase: N/A
Study type: Interventional

The investigators intend to use the Second-generation sequencing(NGS)and MiniPDX drug sensitivity models to guide the treatment decision-making for patients who were resistant to abiraterone, enzalutamide or other new second-generation anti-androgenic drugs. In order to develop precise personalized treatment plans for patients and extent their lifetimes.

NCT ID: NCT03784924 Not yet recruiting - Prostate Cancer Clinical Trials

EDRN Prostate MRI Biomarker Study

P-MRI
Start date: January 2, 2019
Phase:
Study type: Observational

The commercialization of MRI fusion biopsies has resulted in a dramatic increase in the use of MRI imaging for prostate cancer. How best to use MRI in the initial prostate biopsy setting given the availability of validated prostate cancer early detection markers is uncertain.This study will allow investigators to determine if prostate MRI is superior to validated panel of laboratory biomarkers (e.g. PCA3, PSA and TMPRSS2:ERG) in the initial biopsy setting.

NCT ID: NCT03783741 Completed - Prostate Cancer Clinical Trials

The Biopsychosocial Burden of Prostate Biopsy

Start date: January 2014
Phase:
Study type: Observational

Prostate biopsy was offered to 47 consecutive patients with prostate-specific antigen (PSA) over 4 ng/dl or suspicious digital rectal examination (DRE) of whom 16 had undergone a biopsy. Comprehensive validated questionnaires at TIME 0 (pre-biopsy), TIME 1 (before diagnosis, 20 days after biopsy) and TIME 2 (after diagnosis, 40 days after biopsy) accessed patients' erectile (IIEF-5) and voiding (IPSS) functions, Beck scales measured anxiety (BAI), hopelessness (BHS) and depression (BDI), added to the emotional thermometers including five visual analog scales for distress, anxiety, depression, anger and need for help. Mann-Whitney or Friedman tests were obtained among times and studied variables.

NCT ID: NCT03778112 Recruiting - Prostate Cancer Clinical Trials

MRI Guided SBRT for Localized Prostate Cancer

Start date: May 23, 2016
Phase: Phase 2
Study type: Interventional

This study utilizes advanced imaging techniques (mpMRI prostate scan) to select and stratify patients for two different radiotherapy regimens based on the presence/absence of identifiable intraprostatic lesions. In patients without identifiable prostate cancer lesions, SBRT to the prostate in 5 sessions (fractions) will be administered. In patients with MRI-identified lesion(s), pelvic IMRT in 25 fractions will be administered followed by an SBRT prostate boost while simultaneously treating the prostate cancer lesion(s) to a higher dose in 3 fractions.

NCT ID: NCT03777982 Not yet recruiting - Prostate Cancer Clinical Trials

A Randomized Phase III Study - Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Start date: January 30, 2019
Phase: Phase 3
Study type: Interventional

This research study is being offered to those patients who have already received radiation therapy and who are receiving long-term hormonal therapy for their prostate cancer and whose PSA remains detectable (greater than 0.1) despite having received at least 6, but no more than 8 months of hormonal therapy. The name of the study drugs involved in this study is: - LHRHA (luteinizing hormone-releasing hormone agonist or antagonist) - Abiraterone Acetate - Apalutamide - Prednisone

NCT ID: NCT03776045 Completed - Prostate Cancer Clinical Trials

PROState Cancer Patients Initiating Hormone Therapy: Effect of Exercise on CARDIOvascular Health (PROSCARDIO)

PROSCARDIO
Start date: August 12, 2013
Phase: N/A
Study type: Interventional

This study evaluates whether exercise can reduce treatment-related adverse effects in prostate cancer patients initiating androgen deprivation therapy. Half of recruited participants completed a 3-month exercise intervention, while the other half did not perform any supervised exercise. It was anticipated that exercise would have a positive effect on body composition, cardiorespiratory fitness and quality of life.

NCT ID: NCT03770351 Recruiting - Prostate Cancer Clinical Trials

Early Prostate Cancer: Predicting Treatment Response

Start date: January 2017
Phase:
Study type: Observational [Patient Registry]

This study will replicate/validate the risk prediction model developed for the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study in a more diverse patient population to assess generalizability of the model as well as evaluate the relative contribution of the Decipher Prostate Cancer Test and ProstateNext Test from Ambry Genetics, to the risk prediction model for estimating treatment outcomes, and thereby improve personalization of treatment options.

NCT ID: NCT03769766 Not yet recruiting - Prostate Cancer Clinical Trials

Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance

Start date: January 30, 2019
Phase: Phase 3
Study type: Interventional

This is a prospective study to determine if the use of curcumin randomized against placebo will reduce cancer progression in patients with prostate cancer undergoing active surveillance.

NCT ID: NCT03768349 Enrolling by invitation - Prostate Cancer Clinical Trials

Gallium-68 PSMA-11 and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer

Start date: January 3, 2019
Phase: Phase 2
Study type: Interventional

Imaging and staging of prostate cancer is critical for surgical and treatment planning. In this protocol we will image patients with suspected metastatic prostate cancer using 11C-Choline PET and Gallium-68 labeled HBED-CC PSMA (more commonly called 68Ga-PSMA-11) in order to demonstrate their utility in detecting prostate cancer.